Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation

Therapeutic Drug Monitoring

Volumn 34, Issue 6, 2012, Pages 680-685

  Ro, Han ^a   Min, Sang Il ^b   Yang, Jaeseok ^b,c,d   Moon, Kyung Chul ^d   Kim, Yon Su ^c   Kim, Sang Joon ^b   Ahn, Curie ^c,d   Ha, Jongwon ^c,d  

^a Gachon University College of Medicine   (South Korea)

^b Department of Surgery ^*  (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

Author keywords

CYP3A5; intraindividual variability; kidney transplantation; tacrolimus; therapeutic drug monitoring

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; ASIAN; CALCULATION; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CYTOCHROME P-450 CYP3A; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GRAFT REJECTION; HETEROZYGOTE; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRONS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 84870034888     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182731809     Document Type: Article

References (24)

1. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant. 2006;6: 1111-1131.
2. Kahan BD, Keown P, Levy GA, et al. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther. 2002;24:330-350; discussion 29. (Pubitemid 34275858)
3. Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet. 2006;45:905-922. (Pubitemid 44299827)
4. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43: 623-653. (Pubitemid 38981845)
5. Borra LC, Roodnat JI, Kal JA, et al. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-Term outcome after kidney transplantation. Nephrol Dial Transplant. 2010;25:2757-2763.
6. Waiser J, Slowinski T, Brinker-Paschke A, et al. Impact of the variability of cyclosporin A trough levels on long-Term renal allograft function. Nephrol Dial Transplant. 2002;17:1310-1317. (Pubitemid 34812079)
7. Kahan BD, Welsh M, Urbauer DL, et al. Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs. J Am Soc Nephrol. 2000;11:1122-1131. (Pubitemid 30367943)
8. Glowacki F, Lionet A, Buob D, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tacrolimus dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transplant. 2011;26:3046-3050.
9. Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the CYP3A51 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005;79:499-502. (Pubitemid 40280186)
10. Jacobson PA, Oetting WS, Brearley AM, et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011;91:300-308.
11. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997;27:201-214.
12. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914-919. (Pubitemid 38745590)
13. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-760.
14. Min SI, Kim SY, Ahn SH, et al. CYP3A51 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. Transplantation. 2010;90:1394-1400.
15. Pashaee N, Bouamar R, Hesselink DA, et al. CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance. Ther Drug Monit. 2011;33:369-371.
16. Benet LZ. Impact of intraindividual variability of drugs on therapeutic outcomes: lessons from outside transplantation. Transplant Proc. 1998; 30:1650-1651. (Pubitemid 28399263)
17. Tavira B, Coto E, Diaz-Corte C, et al. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med. 2011;49:825-833.
18. Haufroid V, Wallemacq P, VanKerckhove V, et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. Am J Transplant. 2006;6:2706-2713.
19. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-Todose ratio in renal transplant recipients. Transplantation. 2003;76: 1233-1235.
20. Yong Chung J, Jung Lee Y, Bok Jang S, et al. CYP3A53 genotype associated with intrasubject pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit. 2010;32:67-72.
21. Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant. 2005;19:638-643.
22. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254.
23. Maclean JR, Pfister M, Zhou Z, et al. Quantifying the impact of nonadherence patterns on exposure to oral immunosuppressants. Ther Clin Risk Manag. 2011;7:149-156.
24. Kahan BD. High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. Transplant Proc. 1998;30:1639-1641.